Brexpiprazole

ApprovedWithdrawn

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Major Depressive Disorder (MDD)

Conditions

Major Depressive Disorder (MDD)

Trial Timeline

Aug 29, 2022 → Apr 5, 2023

NCT ID

NCT05504486

About Brexpiprazole

Brexpiprazole is a approved stage product being developed by Lundbeck for Major Depressive Disorder (MDD). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05504486. Target conditions include Major Depressive Disorder (MDD).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05504486	Approved	Withdrawn	Aug 29, 2022	Apr 5, 2023	Major Depressive Disorder (MDD)
NCT04830215	Approved	Completed	Apr 1, 2021	May 27, 2022	Major Depressive Disorder
NCT04258839	Phase 3	Completed	Jan 23, 2020	Mar 16, 2023	Irritability Associated With Autism Spectrum Disorder
NCT03548584	Phase 3	Completed	May 16, 2018	Jun 1, 2022	Agitation Associated With Alzheimer's Dementia
NCT03287869	Phase 3	Completed	Oct 24, 2017	Jul 31, 2019	Bipolar I Disorder
NCT03292848	Phase 1	Completed	Oct 10, 2017	May 21, 2018	ADHD
NCT03238326	Phase 3	Completed	Aug 23, 2017	Apr 22, 2025	Schizophrenia
NCT01944969	Phase 3	Terminated	Oct 1, 2013	May 1, 2014	Major Depressive Disorder
NCT01942785	Phase 3	Completed	Oct 1, 2013	—	Major Depressive Disorder
NCT01942733	Phase 3	Completed	Sep 1, 2013	Aug 1, 2014	Sleep Disturbances
NCT01810783	Phase 3	Completed	Jul 1, 2013	Dec 1, 2015	Schizophrenia

Competing Products

20 competing products in Major Depressive Disorder (MDD)

See all competitors

Product	Company	Stage	Hype Score
Duloxetine Hydrochloride	Eli Lilly	Pre-clinical	23
LY2216684	Eli Lilly	Phase 1	33
LY2216684	Eli Lilly	Phase 1	33
Duloxetine	Eli Lilly	Phase 3	77
LY2216684 + Digoxin	Eli Lilly	Phase 1	33
Duloxetine + Paroxetine	Eli Lilly	Phase 3	77
Duloxetine + placebo	Eli Lilly	Phase 3	77
LY2216684 + Placebo + Escitalopram	Eli Lilly	Phase 2	52
FK949E	Astellas Pharma	Phase 1	33
quetiapine extended release (XR) + Placebo	Astellas Pharma	Phase 2	52
FK949E	Astellas Pharma	Phase 1	33
FK949E	Astellas Pharma	Phase 1	33
FK949E	Astellas Pharma	Phase 1	33
Mirtazapine Tablets	Sun Pharmaceutical	Approved	85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1	Ono Pharmaceutical	Phase 2	52
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	52
Pramipexole ER + Escitalopram	Cipla	Phase 2	52
LY2216684 + Sertraline	Eli Lilly	Phase 1	33
LY2216684 + Placebo + Lorazepam	Eli Lilly	Phase 1	33
LY2216684 + SSRI	Eli Lilly	Phase 3	77

Other Products from Lundbeck

VortioxetineApproved

memantine + memantine + placeboApproved

escitalopram + escitalopramApproved

losartan (drug)Approved

vigabatrinApproved